赛沃替尼在Ⅲ/IV期非小细胞肺癌中的疗效观察OA北大核心CSTPCD
Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer
目的 分析赛沃替尼在Ⅲ/iv期非小细胞肺癌(NSCLC)患者中的治疗效果.方法 采用随机数字表法将95例MET 14外显子(METex14)跳跃突变的Ⅲ/Ⅳ期NSCLC患者分为对照组(47例)与观察组(48例).对照组给予克唑替尼治疗,观察组给予赛沃替尼治疗.采用卡方检验分析两组临床疗效及不良反应发生情况,Kaplan-Meier生存分析评估两组患者生存情况.结果 观察组客观缓解率(ORR)和疾病控制率(DCR)分别为52.08％和87.50％,…查看全部>>
Objective To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer(NSCLC).Methods A total of 95 patients with MET 14 exon(METex14)jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group(47 cases)and an observation group(48 cases)through a random-number table method.The patients in the control group were treated with crizotinib,whereas those in the observation group were treated with savolitinib.The clin…查看全部>>
钟诚;张扬;储子昂;钱洪
246004 安庆,海军安庆医院肿瘤中心246004 安庆,海军安庆医院肿瘤中心246004 安庆,海军安庆医院肿瘤中心246004 安庆,海军安庆医院肿瘤中心
临床医学
非小细胞肺癌间质-上皮细胞转化因子赛沃替尼
Non-small cell lung cancerMesenchymal-epithelial transition factorSavolitinib
《肿瘤防治研究》 2024 (3)
191-194,4
评论